Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Biocon makes and sells biologic medicines, generic drugs, and the ingredients that go into other medicines, selling them to drugmakers and healthcare markets around the world.
Biocon is one of India's best-known biotech companies. It makes medicines — especially complex biologic drugs grown in living cells — along with generic pills and capsules and the active chemical ingredients that other drugmakers buy to put into their own products. It sells these to hospitals, pharmacies, and other pharmaceutical companies, mostly in the United States and other big markets, with its home base in Bengaluru, India.
The most interesting part of the business is biosimilars. When a biologic drug loses patent protection, a company can make a near-copy, and regulators can approve it as a cheaper alternative. Making one is far harder than copying a simple pill, because you have to grow the drug in living cells and prove it behaves the same way. Biocon bet big on this, and its biosimilars unit, Biocon Biologics, sells versions of drugs used to treat cancer and autoimmune diseases like rheumatoid arthritis. In 2022 Biocon Biologics bought the biosimilars business of Viatris, which gave it direct control over selling its products in the US and Europe instead of relying on partners. That was a huge strategic shift — more of the profit stays with Biocon — but it also meant debt and the cost of building a sales force, and the integration has weighed on results.
The company also runs a research services arm that does lab work for other drugmakers (it sold a stake in that business to a private investor), and Syngene, a separately listed contract research company it founded. Biocon's story is a bet that making hard-to-copy biologic medicines at lower cost is a durable advantage — and that the payoff will come as more of these drugs lose patent protection in the years ahead.
Saved answer · last researched 15 Nov 2026